Anti-TNF therapy-induced autoimmunity

Volume: 55 Number: 3 September 1, 2016
  • Songül Çildağ Taşkın Şentürk
  • Berna Gültekin
  • Gökhan Sargın
Ege Journal of Medicine Cover
Ege Journal of Medicine
PDF Download
EN TR

Anti-TNF therapy-induced autoimmunity

Abstract

Aim: Anti-TNF therapy has recently emerged as an effective therapy for treating rheumatic diseases. With this increasing use and longer follow-up periods of treatment, various adverse effects are emerging. These adverse effects also include autoimmune processes. The aim of this study was to determine the autoimmune processes after anti-TNF therapy for rheumatic diseases. Materials and Methods: This study included 67 patients who were treated with anti-TNF drugs for rheumatoid arthritis and ankylosing spondylitis. Thirty-two patients with rheumatoid arthritis and thirty-five patients with ankylosing spondylitis were monitered. Thirty-five patients receiving infliximab, sixteen patients receiving adalimumab, sixteen patients receiving etanercept. According to the rheumatic diseases groups and anti-TNF therapies groups, the patients were divided into subgroups. The ANA and anti-dsDNA antibody levels were identified by the immunefluorescence method and ACA antibody levels were identified by the ELISA methods. Results: In this study, the percentages of ANA positivity in sixty-seven patients range from 10.4% to 40.3%. Only one patient had serum level of anti-dsDNA. No patient had serum level of ACA. ANA induction was more important under infliximab than with the two other anti-TNF blockers. No patient developed clinical symptoms of lupus who had been seroconversion of antibody. ANA was not influenced by the underlying rheumatism or anti-TNF combined therapies with methotrexate and corticosteroids. Conclusion: Anti-TNF induced autoantibodies are common following therapy with all of the currently available anti-TNF therapies. However the incidence of anti-TNF inducel lupus is rare.

Keywords

Details

Primary Language

Turkish

Subjects

-

Journal Section

-

Authors

Songül Çildağ Taşkın Şentürk

Berna Gültekin

Gökhan Sargın

Publication Date

September 1, 2016

Submission Date

September 1, 2016

Acceptance Date

-

Published in Issue

Year 2016 Volume: 55 Number: 3

DOI

https://doi.org/10.19161/etd.344209

IZ

https://izlik.org/JA27PN92SM

Cite

RIS / Bibtex
Vancouver
1.Songül Çildağ Taşkın Şentürk, Berna Gültekin, Gökhan Sargın. Anti-TNF tedavilerin tetiklediği otoimmünite. EJM. 2016 Sep. 1;55(3):129-34. doi:10.19161/etd.344209

Ege Journal of Medicine enables the sharing of articles according to the Attribution-Non-Commercial-Share Alike 4.0 International (CC BY-NC-SA 4.0) license.